Wayne Pisano
CIK: 0001743611
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Jun 1, 2026ONCY
ONCOLYTICS BIOTECH INC
Award(A)DirectStock Option
30K shares- - May 1, 2026ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
48.8K shares- - Feb 12, 2026ONCY
ONCOLYTICS BIOTECH INC
Purchase(P)Direct30K shares at avg. $0.84$25K - Jan 8, 2026ALT
Altimmune, Inc.
Purchase(P)Direct5K shares at avg. $4.08$20K - Sep 25, 2025ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
48.8K shares- - Sep 26, 2024ALT
Altimmune, Inc.
Award(A)DirectStock Options (option to buy)
34.9K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 1, 2026 | ONCY ONCOLYTICS BIOTECH INC | Award(A) Stock Option | 30,000 | - | - | Direct |
| May 1, 2026 | ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 48,800 | - | - | Direct |
| Feb 12, 2026 | ONCY ONCOLYTICS BIOTECH INC | Purchase(P) | 30,000 | $0.84 | $25,338 | Direct |
| Jan 8, 2026 | ALT Altimmune, Inc. | Purchase(P) | 5,000 | $4.08 | $20,410 | Direct |
| Sep 25, 2025 | ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 48,800 | - | - | Direct |
| Sep 26, 2024 | ALT Altimmune, Inc. | Award(A) Stock Options (option to buy) | 34,900 | - | - | Direct |
1-6 of 6 transactions
About Pisano Wayne
Pisano Wayne (SEC CIK 0001743611) files insider reports with the SEC as Director of ONCOLYTICS BIOTECH INC (ONCY) and Director of Altimmune, Inc. (ALT).
Signal8 holds 7 ownership filings by Pisano Wayne (1 Form 3, 6 Form 4), filed between Sep 30, 2024 and Jun 3, 2026. Those filings report 6 transactions, from Sep 26, 2024 to Jun 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Pisano Wayne's filings is in SAN DIEGO, CA.
Recent filings by Pisano Wayne
- Jun 1, 2026: Grant or award of ONCY derivative securities (Form 4, code A).
- May 1, 2026: Grant or award of ALT derivative securities (Form 4, code A).
- Feb 12, 2026: Open-market purchase of ONCY shares (Form 4, code P).
- Jan 8, 2026: Open-market purchase of ALT shares (Form 4, code P).
- Sep 25, 2025: Grant or award of ALT derivative securities (Form 4, code A).
Other insiders filing for ONCOLYTICS BIOTECH INC (ONCY)
- McAdory John Bearden, Chief Operating Officer
- RIGBY JONATHAN, Director
- Holtham Angela, Director
- Parsons James T., Director
- Look Kirk, Chief Financial Officer
- Aromando Andrew, Chief Business Officer